EUVIMEDEUVIMED entdecken
Multizentrische Studie

Unmasking isoniazid resistance in rifampicin-susceptible TB: a national multicentre study using Xpert MTB/XDR

E M Goshu, A G Woldegiorgis, Z G Dememew, E D Gebremedihin, A A Tsega, T B Abraha, T A Abagero, J S Mohammed, D T Mekuria, G A Doti, T L Janfa, E A Abdisa und 3 weitere

The International Journal of Tuberculosis and Lung Disease · 2026

DOI: 10.5588/ijtld.26.0111 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2026. Verfasst von E M Goshu und 14 weiteren Autor:innen. Beteiligte Einrichtung: KNCV Tuberculosis Foundation, Addis Ababa, Ethiopia. Hauptthemen laut MEDLINE: Rifampin, Isoniazid, Antitubercular Agents, Mycobacterium tuberculosis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND

TB remains a major global health threat, worsened by drug resistance. Hr-TB (isoniazid resistance) in rifampicin-susceptible cases compromises outcomes. This study used Xpert MTB/XDR to determine Hr-TB prevalence and associated risk factors, informing national control strategies.





METHOD

A cross-sectional study was conducted in 74 Ethiopian health facilities (May–October 2024), including 841 rifampicin-susceptible TB cases. Hr-TB was evaluated using the Xpert MTB/XDR assay. Two-stage sampling and logistic regression estimated prevalence and identified significant predictors.





RESULTS

The overall Hr-TB prevalence was 2.7%, higher among previously treated TB cases (16.2%) than in new TB cases (0.9%). Regional variation showed the highest prevalence in Gambella (7.1%), Oromia (6.2%), and Sidama (5.7%). Multivariable analysis identified prior TB treatment as the main predictor, including other previously treated cases (AOR = 138.48), relapses (AOR = 5.59), and history of treatment after failure (AOR = 45.51).





CONCLUSIONS

Hr-TB remains a significant concern among rifampicin-susceptible TB patients in Ethiopia, particularly in previously treated cases, with regional variation underscoring a persistent challenge. Strengthening routine isoniazid resistance testing, expanding access to Xpert MTB/XDR, improving treatment adherence, and implementing targeted interventions with enhanced surveillance are essential to prevent resistance amplification, improve outcomes, and control Hr-TB spread.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinIsoniazidAntitubercular AgentsMycobacterium tuberculosisExtensively Drug-Resistant TuberculosisTuberculosis, Multidrug-ResistantHumansEthiopiaCross-Sectional StudiesPrevalenceRisk FactorsFemaleMale

Substanzen

RifampinIsoniazidAntitubercular Agents

Autor:innen und Institutionen

  • KNCV Tuberculosis Foundation, Addis Ababa, Ethiopia.
  • Management Science for Health, Addis Ababa, Ethiopia.
  • The Federal Ministry of Health, Addis Ababa, Ethiopia.
  • Ethiopia Public Health Institute, Addis Ababa, Ethiopia.

Zitieren

APA

Goshu, E. M., Woldegiorgis, A. G., Dememew, Z. G., Gebremedihin, E. D., Tsega, A. A., Abraha, T. B., Abagero, T. A., Mohammed, J. S., Mekuria, D. T., Doti, G. A., Janfa, T. L., Abdisa, E. A., Kasaie, Y., Kumsa, A., & Datiko, D. G. (2026). Unmasking isoniazid resistance in rifampicin-susceptible TB: a national multicentre study using Xpert MTB/XDR. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.26.0111

Vancouver

Goshu EM, Woldegiorgis AG, Dememew ZG, Gebremedihin ED, Tsega AA, Abraha TB, et al. Unmasking isoniazid resistance in rifampicin-susceptible TB: a national multicentre study using Xpert MTB/XDR. The International Journal of Tuberculosis and Lung Disease. 2026. doi:10.5588/ijtld.26.0111

BibTeX
@article{Goshu2026,
  author = {Goshu, E M and Woldegiorgis, A G and Dememew, Z G and Gebremedihin, E D and Tsega, A A and Abraha, T B and Abagero, T A and Mohammed, J S and Mekuria, D T and Doti, G A and Janfa, T L and Abdisa, E A and Kasaie, Y and Kumsa, A and Datiko, D G},
  title = {Unmasking isoniazid resistance in rifampicin-susceptible TB: a national multicentre study using Xpert MTB/XDR},
  journal = {The International Journal of Tuberculosis and Lung Disease},
  year = {2026},
  doi = {10.5588/ijtld.26.0111}
}
Kostenlos starten →